NMD Pharma
NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence. NMD Pharma wins EY
Basic Information
- Category: business
- Founded: 2015
- Website: http://www.nmdpharma.com/
Documented Facts
- Email: user@domain.com (No linked source recorded for this statement.)
- Team Size: 60 (No linked source recorded for this statement.)
- Founded: 2015 (No linked source recorded for this statement.)
- Website: http://www.nmdpharma.com/ (No linked source recorded for this statement.)
- Headquarters: Aarhus, Denmark (No linked source recorded for this statement.)
- Employees: 60 (No linked source recorded for this statement.)
Evidence and Sources
- NMD Pharma — Official Site (official)
- NMD Pharma on instagram (social)
- NMD Pharma on facebook (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about NMD Pharma.
- Canonical profile: https://brandsource.ai/brands/nmd-pharma
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/nmd-pharma/json-ld
- Citation profile API: https://brandsource.ai/api/brands/nmd-pharma/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence. NMD Pharma wins EY
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 6 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.